InvestorsHub Logo
Followers 32
Posts 3725
Boards Moderated 0
Alias Born 09/04/2007

Re: None

Thursday, 04/17/2008 1:32:50 PM

Thursday, April 17, 2008 1:32:50 PM

Post# of 302225
IDTA plans to re-purchase stock.

(credit to :reference to news posted by garagist on the IDTA board)

IDenta Corp. Announces Plan To Re-Purchase Stock.Apr 17, 2008
Pink OTC Markets News Service

Jerusalem, Israel— Jerusalem, Israel April 17, 2008- The Board of Directors of IDenta Corp. (OTC Pink Sheets: IDTA) announced today that it as approved a program to re-purchase and retire outstanding shares of the company's common stock to the treasury.

A prepared statement issued by the company read:
"The Board of IDenta Corp., based on our perception of the current market valuation of our company, has voted to a plan to repurchase shares of IDTA common stock in the open market. Funding for the initial phase of the program has also been approved and the buy back program is effective immediately.

IDenta is entering a new era as an internationally respected company with growing sales, new patents, a broadening, superior product line of chemical detectors and an established marketing network that is opening up new opportunities daily. We feel that it is now in the best interest of IDenta and our long-term shareholders to take this course of action to significantly reduce the public float of the company's shares.

The board will carefully monitor and analyze the share price during the next three months in order to determine the exact number of shares that will be repurchased."

About IDenta
Since 2003, IDenta Corporation has become recognized as a worldwide leader in the development of proprietary on-site drug and explosive detection kits, and soon to be chemical precursor detectors. IDenta develops, manufactures and distributes products for the both professional and civil markets that consistently pass the highest qualifications and testing procedures of law enforcement and security agencies around the world. Information concerning IDenta's entire product line may be found at www.IDenta.biz.

Disclaimer

Certain of the statements contained herein may be, within the meaning of the federal securities laws, "forward-looking statements" that are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements are based on management's expectations as of the date hereof, and the company does not undertake any responsibility to update any of these statements in the future.

Contact:
Contact:
For Investor Relations, lobbying interests or information concerning
IDenta's products internationally, contact:
Yaacov Shoham
IDenta Corp.
CEO
Tel: +972-52-6554487
fpi@drugsdetector.com

For Investor Relations in the US, contact:
Randy Jacobs
Corporate Spokesman
IDentaNews@sitcomllc.com
1-800-316-9437

For information about the Accutest? -- IDenta products in the US, please
contact:
Mr. Eyal Golan
COO
JANT PHARMACAL CORPORATION
16255 Ventura Blvd. #505
Encino, CA 91436
Toll Free: 800-676-5565
http://www.accutest.net


Source: IDenta Corp.

The above news release has been provided by the above company via Pink Sheets News Service. Issuers of news releases and not Pink Sheets are solely responsible for the accuracy of such news releases

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.